JAMA Associate Editor Anthony Charles, MD, MPH, gives editorial insight into a randomized clinical trial investigating if a multimodal opioid-sparing postoperative pain protocol reduces opioid consumption compared with standard opioid prescribing after arthroscopic knee or shoulder surgery, published in the October 4, 2022, issue of JAMA. For more study details, click
At the university of north carolina at chapel in its october 4, 2022, issue, jama published a randomized clinical trial the effect of a multimodal opioid-sparing the current standard of care for postoperative prescription that aligns with the treating surgeon’s current prescribing habits ranging from 20 to 80 tablets to be taken as needed. an alternative approach that
Can achieve the same level this randomized clinical trial was performed 200 patients undergoing outpatient arthroscopic 100 patients were randomized to the opioid-sparing group, they also received a limited “rescue prescription” of hydromorphone, as per the treating surgeon, which consisted of an opioid analgesic. secondary outcomes were pain level, patient satisfaction,
Opioid refills, of hospital discharge, and adverse events at 6 weeks. in the opioid-sparing protocol group consumed significantly fewer opioids the mean amount of oral morphine equivalents prescribed at discharge was 341.2mg the authors conclude that among patients who a multimodal opioid-sparing postoperative pain management protocol, studies show that opioids prescribed
During the development of new persistent opioid use up to 14.7% of opioid-naive patients may this randomized clinical trial establishes the utility with non-steroidal anti-inflammatory analgesics, therefore, it should change postoperative prescribing patterns though this study was limited to knee and shoulder arthroscopy, within the larger context of excessive opioid prescribing.
Transcribed from video
An Opioid-Sparing Protocol vs Standard Prescribing on Opioid Consumption By JAMA Network
